

Curriculum Vitae
Prof. Mohammad A. Khanfar

Email: mkhanfar@alfaisal.edu m_khanfar@ju.edu.jo mhm512@hotmail.com

Education

- 2007 – 2010** PhD in Medicinal Chemistry and Drug design, College of Pharmacy, University of Louisiana at Monroe, USA. GPA 3.91/4.00, Thesis title: “Computer-Assisted Design and Discovery of Actin Polymerization and GSK-3 β Inhibitors based on Marine Natural Products”.
- 2005 – 2007** MSc in Pharmaceutical Science, College of Pharmacy, University of Jordan, GPA 4.00/4.00, Thesis title: “Preparation and Characterization of Organic salts of Valproic Acid”.
- 1999 – 2004** BSc Pharmacy, College of Pharmacy, University of Jordan, GPA: 3.80/4.00.

Professional Experience

- 2023– Present** Vice Dean of Academic Affairs, Research, and Graduate Studies at College of Pharmacy, Alfaisal University, Riyadh, KSA.
- 2020– Present (Unpaid leave)** Professor of Drug Design and Medicinal Chemistry, Department of Pharmaceutical Sciences, Faculty of Pharmacy, The University of Jordan, Amman, Jordan.
- 2022 - Present** Professor of Drug Design and Medicinal Chemistry, Department of Pharmaceutical Sciences, College of Pharmacy, Alfaisal University, Riyadh, KSA
- 2017– 2022** Associate Professor of Drug Design and Medicinal Chemistry, Department of Pharmaceutical Sciences, College of Pharmacy, Alfaisal University, Riyadh, KSA
- 2017 – 2019** Head of Department of Pharmaceutical Sciences, College of Pharmacy, Alfaisal University, Riyadh, KSA
- 2019 – 2020**
2015 – 2016 Head of Department of Pharmaceutical Sciences, Faculty of Pharmacy, The University of Jordan, Amman, Jordan.
- 2015– 2020** Associate Professor of Drug Design and Medicinal Chemistry, Department of Pharmaceutical Sciences, Faculty of Pharmacy, The University of Jordan, Amman, Jordan.

2015 – Present	Alexander von Humboldt Fellow, Heinrich Heine University Düsseldorf and Frei Universität Berlin, Germany
2013 – 2016	Adjunct Professor at College of Pharmacy, University of Louisiana at Monroe, Monroe, USA
2011 – 2015	Assistant Professor of Drug Design and Medicinal Chemistry, Department of Pharmaceutical Sciences, Faculty of Pharmacy, The University of Jordan.
2010 – 2011	NIH Postdoctoral Fellow of Professor Richard B. Silverman (the inventor of Lyrica®), Center of Molecular Innovation and Drug Discovery (CMIDD), Department of Chemistry, Northwestern University, Chicago, USA.

Publications

- 1) **Mohammad A. Khanfar**, Nada Salaas (2024): 3-(phenylsulfonamido)benzamide Derivatives as Potent Carbonic Anhydrase IX Inhibitors. Submitted to Bioorganic & Medicinal Chemistry Letters.
- 2) **Mohammad A. Khanfar**, Mohammad Saleh (2023): SARS-CoV-2 Main Protease Inhibitors from Natural Product Repository as Therapeutic Candidates for Treatment of Coronaviridae Infections. Phototherapy Research (**IF** = **7.2**) Accepted.
- 3) **Mohammad A. Khanfar**, Nada Salass, Reem Abumostafa (2023): Discovery of Natural-Derived Mpro Inhibitors as Therapeutic Candidates for COVID-19: Structure-Based Pharmacophore Screening Combined with QSAR Analysis. Molecular Informatics (**IF** = **4.05**). 42 (4) 2200198.
- 4) **Mohammad A. Khanfar**, Ibrahim M Salman, Omar Z Ameer (2022): Synthesis and Biological Evaluation of Thiazole-Based Fibroblast Growth Factor Receptor-1 Inhibitors. Anti-cancer Agents in Medicinal Chemistry (**I.F.** = **2.50**), DOI: 10.2174/1871520622666220905141248
- 5) **Mohammad A. Khanfar** (2022): Novel Oxadiazol-Based mTOR inhibitors with Potent Antiproliferative Activities. Synthetic and Computational Modeling. Molecular Diversity (**I.F.** = **3.36**), 26, 3357–3364.
- 6) **Mohammad Khanfar** (2021): Structure-Based Pharmacophore Screening Coupled with QSAR Analysis Identified Potent Natural-Product-Derived IRAK-4 Inhibitors. Molecular Informatics (**I.F.** = **4.05**), 40 (12) 2100025.
- 7) **Mohammad Khanfar**, Saja Alqtaishat (2021): Discovery of Potent Natural-Product-Derived SIRT2 Inhibitors Using Structure-Based Exploration of SIRT2 Pharmacophoric

Space Coupled with QSAR Analyses. Anti-cancer Agents in Medicinal Chemistry (**I. F.** = **2.50**), 21 (16) 2278 – 2286.

- 8) Jens Hagenow, Stefanie Hagenow, Kathrin Grau, **Mohammad Khanfar**, Lena Hefke, Ewgenij Proschak Holger Stark (2020): Reversible Small Molecule Inhibitors of MAO A and MAO B with Anilide Motifs. Drug Design, Development and Therapy (**I.F.** = **4.16**), 13, 1–23.
- 9) Bathini Thissera, Rizliya Visvanathan, **Mohammad Khanfar**, Mallique Qader, Marwa Hassan, Hossam Hassan, Majed Bawazeer, Fathy Behery, Mohammed Yaseen, Ruvini Liyanage, Mostafa Rateb (2020): Sesbania grandiflora L. Poir leaves: A dietary supplement to alleviate type 2 diabetes through metabolic enzymes inhibition. South African Journal of Botany (**I.F.** = **2.31**), 130, 282-299.
- 10) Abeer Elmaidomy, Rabab Mohammed, Hossam M. Hassan, Asmaa I. Owis, Mostafa E. Rateb, **Mohammad A. Khanfar**, Markus Krischke, Martin J. Mueller, Usama Ramadan Abdelmohsen (2019): Metabolomic Profiling and Cytotoxic Tetrahydrofuran Lignans Investigations from Premna odorata Blanco. Metabolites (**I.F.** = **4.93**), 9, 223.
- 11) **Mohammad A. Khanfar**, SajaAlqtaishat (2019): Discovery of potent IRAK-4 inhibitors as potential anti-inflammatory and anticancer agents using structure-based exploration of IRAK-4 pharmacophoric space coupled with QSAR analyses. Computational Biology and Chemistry (**I.F.** = **2.88**), 79, 147-154.
- 12) Seham S El-Hawary, Ahmed M Sayed, Rabab Mohammed, **Mohammad Khanfar**, Mostafa E Rateb, Tarek A Mohammed, Dina Hajjar, Hossam M Hassan, Tobias A. M Gulder, Usama Ramadan Abdelmohsen (2018): New Pim-1 kinase inhibitor from the co-culture of two sponge-associated actinomycetes. Frontiers in Chemistry (**I.F.** = **5.22**), 6, 538.
- 13) **Mohammad A Khanfar**, David Reiner, Stefanie Hagenow, Holger Stark (2018): Design, Synthesis, and Biological Evaluation of Novel Oxadiazole- and Thiazole-Based Histamine H3R Ligands. Bioorganic and Medicinal Chemistry (**I.F.** = **3.64**), 26 (14): 4034 – 4046.
- 14) Rasha Bashatwah, **Mohammad A Khanfar**, Sanaa Bardaweel (2018): Discovery of potent polyphosphate kinase 1 (PPK1) inhibitors using structure-based exploration of PPK1Pharmacophoric space coupled with docking analyses. Journal of Molecular Recognition (**I.F.** = **2.18**), 31(10): e2726.
- 15) **Mohammad A Khanfar**, Mutasem Taha (2017): Unsupervised pharmacophore modeling combined with QSAR analyses revealed novel low micromolar SIRT2 inhibitors. Journal of Molecular Recognition (**I.F.** = **2.18**), 30(9): e2623.
- 16) Haneen Khaled Mohammad, Muhammed H. Alzweiri, **Mohammad A Khanfar**, Yusuf Al-Hiari (2017): 6-Substituted nicotinic acid analogues, potent inhibitors of CAIII, used as therapeutic candidates in hyperlipidemia and cancer. Medicinal Chemistry Research (**I.F.**

= **1.96**), 26 (7): 1397 – 1404.

- 17) Mohammad A. Khanfar**, Fahmy Banat, Shada Alabed, Saja Alqtaishat (**2017**): Discovery of potent NEK2 inhibitors as potential anticancer agents using structure-based exploration of NEK2 pharmacophoric space coupled with QSAR analyses. *Molecular Diversity* (**I.F.** = **2.23**), 21: 187.
- 18) Wafa A Mera**, Malek Alzihlif, Mutasem O Taha, **Mohammad A. Khanfar** (**2017**): Discovery of Potent Bruton's Tyrosine Kinase Inhibitors Using Ligand Based Modeling. *Anti-Cancer Agents in Medicinal Chemistry* (**I.F.** = **2.72**), 17(2):265-275.
- 19) Sara Al-Marabeh**, Enam Khalil, **Mohammad A. Khanfar**, Amal G. Al-Bakri, Muhammed Alzweiri (**2017**): A prodrug approach to enhance azelaic acid percutaneous availability. *Pharmaceutical Development and Technology* (**I.F.** = **3.13**), 22 (4): 578 – 586.
- 20) Shada J. Alabed**, **Mohammad Khanfar**, Mutasem O. Taha (**2017**): Computer-Aided Discovery of new FGFR-1 Inhibitors followed by In vitro Validation. *Future Medicinal Chemistry* (**I.F.** = **3.97**), 8(15):1841-1869.
- 21) Mohammad A. Khanfar**, Saja Al-Qtaishat, Maha Habash, Mutasem O. Taha (**2016**): Discovery of potent adenosine A2a antagonists as potential anti-Parkinson disease agents. Non-linear QSAR analyses integrated with pharmacophore modeling, *Chemico-Biological Interactions* (**I.F.** = **5.19**), 254:93-101.
- 22) Mohammad A. Khanfar**, Anna Affini, Kiril Lutsenko, Katarina Nikolic, Stefania Butini, Holger Stark (**2016**): Multiple Targeting Approaches on Histamine H3 Receptor Antagonists. *Frontiers in Neuroscience* (**I.F.** = **4.68**), 10:201
- 23) Jarrar, N.**, Alzweiri¹, M., Al-Hiari¹, Y., Farah, S., **Khanfar, M. A.** (**2016**): Modified Hummel–Dreyer method and Molecular Modeling Studies Identified Nicotinic Acid Analogues as Carbonic Anhydrase III Ligands. *Letters in Drug Design & Discovery* (**I.F.** = **1.17**), 12 (10): 401-410.
- 24) Khanfar, M. A.**, Bardaweel, S. K., Akl, M. R. El Sayed, K. A. (**2015**): Olive Oil-derived Oleocanthal as Potent Inhibitor of Mammalian Target of Rapamycin: Biological Evaluation and Molecular Modeling Studies. *Phytotherapy Research* (**I.F.** = **5.88**), 29 (11):1776-82.
- 25) Jaradat, N. J.**, **Khanfar, M. A.**, Habash, M., Taha, M. O. (**2015**): Combining docking-based comparative intermolecular contacts analysis and k-nearest neighbor correlation for the discovery of new check point kinase 1 inhibitors. *Journal of Computer-Aided Molecular Design* (**I.F.** = **3.36**), 29, 561-581.
- 26) Khanfar, M. A.**, Quinti, L., Wang, H., Nobles, J., Kazantsev, A. J., Silverman, R. B. (**2015**): Design and Evaluation of 3-(Benzylthio)benzamide Derivatives as Potent and

Selective SIRT2 Inhibitors. ACS Medicinal Chemistry Letters (**I.F.** = **3.79**), 6, 607–611.

- 27) Alzweiri, M., **Khanfar, M. A.**, Al-Hiari, Y. (2015): Variation in GC-MS responses between analytes and deuterated analogues. Chromatographia (**I.F.** = **1.40**), 78, 251-258.
- 28) Taha, M. O., **Khanfar, M. A.** (2015): Oleuropein Potently Inhibits Mammalian Target of Rapamycin: Possible Involvement of Tandem Anomeric Hyperconjugation–Michael Reaction. Medicinal Chemistry Research (**I.F.** = **1.61**), 24, 616-623.
- 29) Taha, M. O., A.Al-Sha'er, M., **Khanfar, M. A.** (2014): Discovery of Nanomolar Phosphoinositide 3-kinase gamma (PI3K γ) Inhibitors Using Ligand-Based Modelling and Virtual Screening followed by In Vitro Analysis. European Journal Of Medicinal Chemistry (**I.F.** = **4.82**), 84, 454–465
- 30) Taha, M. O., Habash, M., **Khanfar, M. A.** (2014): The use of docking-based comparative intermolecular contacts analysis to identify optimal docking conditions within glucokinase and to discover of new GK activators. Journal of computer-aided molecular design (**I.F.** = **3.36**), 28, 509-547.
- 31) **Khanfar, M. A.**, Quinti, L., Wang, H., Choi, S. H., Kazantsev, A. G., Silverman, R. B. (2014): Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors. European journal of medicinal chemistry (**I.F.** = **4.82**), 76, 414-426.
- 32) Al-Sha'er, M. A., **Khanfar, M. A.**, Taha, M. O., (2014): Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis. Journal of molecular modeling (**I.F.** = **1.74**), 20, 2080.
- 33) Abulateefeh, S. R., **Khanfar, M. A.**, Al Bakain, R. Z., Taha, M. O. (2014): Synthesis and characterization of new derivatives of alginic acid and evaluation of their iron(III)-crosslinked beads as potential controlled release matrices. Pharmaceutical development and technology (**I.F.** = **1.95**), 19, 856-867.
- 34) **Khanfar, M. A.**, Taha, M. O. (2013): Elaborate ligand-based modeling coupled with multiple linear regression and k nearest neighbor QSAR analyses unveiled new nanomolar mTOR inhibitors. Journal of chemical information and modeling (**I.F.** = **3.81**), 53, 2587-2612.
- 35) Alzweiri, M., Tarawneh, R., **Khanfar, M. A.** (2013): Gas chromatography/trace analysis of derivatized azelaic acid as a stability marker. Journal of separation science (**I.F.** = **2.74**), 36, 3200-3205.
- 36) Eterovic, V. A., Del Valle-Rodriguez, A., Perez, D., Carrasco, M., **Khanfar, M. A.**, El Sayed, K. A., Ferchmin PA (2013): Protective activity of (1S,2E,4R,6R,7E,11E)-2,7,11-cembratriene-4,6-diol analogues against diisopropylfluorophosphate neurotoxicity: preliminary structure-activity relationship and pharmacophore modeling. Bioorganic &

medicinal chemistry (**I.F.** = **2.88**), 21 (15):4678-4686.

- 37) Khanfar, M. A.,** AbuKhader, M. M., Alqtaishat, S., Taha, M. O. (**2013**): Pharmacophore modeling, homology modeling, and in silico screening reveal mammalian target of rapamycin inhibitory activities for sotalol, glyburide, metipranolol, sulfamethizole, glipizide, and pioglitazone. *Journal of molecular graphics & modelling* (**I.F.** = **1.89**), 42:39-49.
- 38) Khanfar, M. A.,** El Sayed, K. A. (**2013**): The Veratrum alkaloids jervine, veratramine, and their analogues as prostate cancer migration and proliferation inhibitors: biological valuation and pharmacophore modeling. *Medicinal Chemistry Research* (**I.F.** = **1.61**), 22: 4775-4786.
- 39) Hassan, H. M., Elnagar, A. Y., Khanfar, M. A.,** Sallam, A. A., Mohammed, R., Shaala, L. A., Youssef, D. T., Hifnawy, M. S., El Sayed, K. A. (**2011**) Design of semisynthetic analogues and 3D-QSAR study of eunicellin-based diterpenoids as prostate cancer migration and invasion inhibitors. *European journal of medicinal chemistry* (**I.F.** = **4.82**), 46:1122-1130.
- 40) Baraka, H. N., Khanfar, M. A.,** Williams, J. C., El-Giar, E. M., El Sayed, K. A. (**2011**): Bioactive natural, biocatalytic, and semisynthetic tobacco cembranoids. *Planta medica* (**I.F.** = **2.49**), 77:467-476.
- 41) Mudit, M., Khanfar, M.,** Shah, G. V., Sayed, K. A. (**2011**): Methods for evaluation of structural and biological properties of antiinvasive natural products. In: *Methods in Molecular Biology. Drug Design and Discovery*, Ed. Satyanarayanajois, S, D. (Humana Press) 55-71.
- 42) Abraham, I., Jain, S., Wu, C. P., Khanfar, M. A.,** Kuang, Y., Dai, C. L., Shi, Z., Chen, X., Fu, L., Ambudkar, S. V., El Sayed, K., Chen, Z. S. (**2010**): Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells. *Biochemical pharmacology* (**I.F.** = **5.09**), 80:1497-1506.
- 43) Khanfar, M. A.,** Hill, R. A., Kaddoumi, A., El Sayed, K. A. (**2010**): Discovery of novel GSK-3 β inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand- and structure-based virtual screening. *Journal of medicinal chemistry*, (**I.F.** = **6.25**) 53:8534-8545.
- 44) Khanfar, M. A.,** El Sayed, K. A. (**2010**): Phenylmethylene hydantoins as prostate cancer invasion and migration inhibitors. CoMFA approach and QSAR analysis. *European journal of medicinal chemistry* (**I.F.** = **4.82**), 45:5397-5405.
- 45) Khanfar, M. A.,** Youssef, D. T., El Sayed, K. A. (**2010**): 3D-QSAR studies of latrunculin-based actin polymerization inhibitors using CoMFA and CoMSIA approaches. *European journal of medicinal chemistry* (**I.F.** = **4.82**), 45:3662-3668.

- 46) Hassan, H. M., **Khanfar, M. A.**, Elnagar, A. Y., Mohammed, R., Shaala, L. A., Youssef, D. T., Hifnawy, M. S., El Sayed, K. A. (2010): Pachycladins A-E, prostate cancer invasion and migration inhibitory Eunicellin-based diterpenoids from the red sea soft coral *Cladiella pachyclados*. *Journal of natural products* (**I.F.** = **3.89**), 73:848-853.
- 47) Abdel Bar, F. M., **Khanfar, M. A.**, Elnagar, A. Y., Badria, F. A., Zaghloul, A. M., Ahmad, K. F., Sylvester, P. W., El Sayed, K. A. (2010): Design and pharmacophore modeling of biaryl methyl eugenol analogs as breast cancer invasion inhibitors. *Bioorganic & medicinal chemistry* (**I.F.** = **2.88**), 18:496-507.
- 48) **Khanfar, M. A.**, Youssef, D. T., El Sayed, K. A. (2010): Semisynthetic latrunculin derivatives as inhibitors of metastatic breast cancer: biological evaluations, preliminary structure-activity relationship and molecular modeling studies. *ChemMedChem* (**I.F.** = **3.23**), 5:274-285.
- 49) Bar F. M., **Khanfar, M. A.**, Elnagar, A. Y., Liu, H., Zaghloul, A. M., Badria, F. A., Sylvester, P. W., Ahmad, K. F., Raisch, K. P., El Sayed, K. A. (2009): Rational design and semisynthesis of betulinic acid analogues as potent topoisomerase inhibitors. *Journal of natural products* (**I.F.** = **3.89**), 72:1643-1650.
- 50) **Khanfar, M. A.**, Asal, B. A., Mudit, M., Kaddoumi, A., El Sayed, K. A. (2009): The marine natural-derived inhibitors of glycogen synthase kinase-3 β phenylmethylene hydantoins: In vitro and in vivo activities and pharmacophore modeling. *Bioorganic & medicinal chemistry* (**I.F.** = **2.88**), 17:6032-6039.
- 51) Shah, G. V., Muralidharan, A., Thomas, S., Gokulgandhi, M., Mudit, M., **Khanfar, M.**, El Sayed, K. (2009): Identification of a small molecule class to enhance cell-cell adhesion and attenuate prostate tumor growth and metastasis. *Molecular cancer therapeutics* (**I.F.** = **5.76**), 8:509-520.
- 52) Mudit, M., **Khanfar, M.**, Muralidharan, A., Thomas, S., Shah, G. V., van Soest, R. W., El Sayed, K. A. (2009): Discovery, design, and synthesis of anti-metastatic lead phenylmethylene hydantoins inspired by marine natural products. *Bioorganic & medicinal chemistry* (**I.F.** = **2.88**), 17:1731-1738.
- 53) El Sayed, K. A., **Khanfar, M. A.**, Shallal, H. M., Muralidharan, A., Awate, B., Youssef, D. T., Liu, Y., Zhou, Y. D., Nagle, D. G., Shah, G. (2008): Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells. *Journal of natural products* (**I.F.** = **3.89**), 71:396-402.

Patents

- 1) Silverman, R. B., Wang, H., **Khanfar, M. A.**: Benzamide Compounds and Related Methods of Use. Submitted as: U. S. Patent (Application No 14292087, provisionally filed on December 21, 2012).
- 2) El Sayed, K. A., **Khanfar, M. A.**: Latrunculin-Based Macrolides and Their Uses. U. S.

patent (Application No US20110136880 A1, application date 09.06.2011).

Book Chapter

Mudit, M., **Khanfar, M.**, Shah, G. V., Sayed, K. A. (2011): Methods for evaluation of structural and biological properties of antiinvasive natural products. In: Methods in Molecular Biology. Drug Design and Discovery, Ed. Satyanarayanajois, S, D. (Humana Press) 55-71.

Awards

- 1) Faculty Awards for Research Excellence 2019, Alfaisal University, Riyadh, KSA, May **2019**.
- 2) The Outstanding research award of 2014 in the field of pharmacy and medicine, Scientific Research Support Fund (SRF), Ministry of Higher Education, Amman, Jordan, January **2016**.
- 3) The world academy of sciences (TWAS) Young Affiliate Fellow, Trieste, Italy, **2015-2019**
- 4) Georg Forster Research Fellowship (HERMES) for Experienced Research sponsored by Alexander von Humboldt Foundation, Germany, March **2015**.
- 5) American Chemical Society (ACS), Travel Award from the Division of Biological Chemistry to attend Anaheim ACS National meeting, Anaheim, California, **2011**.
- 6) Outstanding Graduate Student Award, College of Pharmacy, University of Louisiana at Monroe, **2011**.
- 7) Graduate Student Symposium Awards in Drug Design and Discovery, American Association of Pharmaceutical Sciences (AAPS), New Orleans, LA, **2010**.
- 8) ULM 9th Annual Student Research Symposium, April 21, **2009**, Monroe, LA. Third place winner, graduate student seminar.
- 9) ULM 8th Annual Student Research Symposium, April 30, **2008**, Monroe, LA. Third place winner, graduate student poster.

Selected Podium Presentation

- 1) Mohammad Khanfar, Discovery of Potent mTOR inhibitors as Potential Anticancer agents, Int. Conf.: Humboldt Kolleg "Jordanian Life Sciences for Sustainable Development", Amman, Jordan, 27 – 29 April 2017.
- 2) Mohammad Khanfar, New Virtual Methodology Identified New mTOR Inhibitors as Potential Anticancers, TWAS 11th Annual Meeting Green Economy: A Road Map for Sustainable Development and Poverty Reduction in the Arab Region, Alexandria, Egypt, 16–17 December 2015
- 3) Mohammad Khanfar, Pharmacophore Modeling Coupled with QSAR Analyses Unveiled New mTOR Inhibitors from the NCI, Drug, and Natural-Product Databases, TWAS 26th General Meeting & Regional Meetings, Vienna, Austria, 18-21 November 2015
- 4) Mudit, M. Mohammad Khanfar, Bhushan Awate, Girish Shah, Khalid El Sayed. Novel

marine -derived leads for metastatic prostate cancer. 8th Annual Student Research Symposium, ULM, Monroe, LA, April 30, 2008.

- 5) Mohammad A. Khanfar, Diao T. A. Youssef, and Khalid A. El Sayed. Latrunculin A and its C-17-O-Carbamates as Potent Anti-invasive Prostate Cancer Leads. The 35th Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, May 18-20, 2008, Little Rock, AR.
- 6) Mudit M, Khanfar M, Awate B, Shah GV, El Sayed KA. Novel marine-derived leads for metastatic prostate cancer. The 35th Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, May 18-20, 2008, Little Rock, AR.
- 7) Mohammad A. Khanfar, Diao T. A. Youssef, and Khalid A. El Sayed. Rationale Design of Semisynthetic Latrunculin Analogs as Inhibitors for Metastatic Breast Cancer, Preliminary Structure Activity Relationship, and Three- Dimensional Quantitative Structure-Activity Relationship (3D QSAR) Studies. The 36th Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, May 17-19, 2009, Memphis, TN.
- 8) Mudit M, Khanfar M, Muralidharan A, Thomas S, Shah GV, El Sayed KA. Phenylmethyle hydantoin analogues: Promising leads for the treatment of metastatic prostate cancer. ULM 9th Annual Research Symposium, Apr 21, 2009, Monroe, LA.
- 9) Mohammad A. Khanfar, Diao T. A. Youssef and Khalid A. El Sayed. Rationale Design of Semisynthetic Latrunculin Analogs as Inhibitors for Metastatic Breast Cancer, Preliminary Structure-Activity Relationship, and Three- Dimensional Quantitative Structure-Activity Relationship (3D QSAR) Studies. ULM 9th Annual Research Symposium, Apr 21, 2009, Monroe, LA.
- 10) Mudit M, Khanfar M, Muralidharan A, Thomas S, Shah GV, El Sayed KA. Phenylmethyle hydantoins and their anti-metastatic potential against advanced prostate cancer. The 36th Annual MALTO Medicinal Chemistry-Pharmacognosy Meeting, May 17-19, 2009, Memphis, TN.
- 11) Mudit M, Khanfar M, Muralidharan A, Thomas S, Shah GV, El Sayed KA. Discovery, design, and synthesis of anti-metastatic lead phenylmethyle hydantoins. American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, Nov 8-12, 2009, Los Angeles, CA.
- 12) Mohammad Khanfar, Ronald Hill, Amal Kaddoumi, Khalid El Sayed. Computer-Assisted Discovery, Design, Synthesis, In Vitro, and In Vivo Evaluations of Highly Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 β . American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, Nov 13-18, 2010, New Orleans, LA.

Selected Poster Presentations

- 1) Mohammad Khanfar, Holger Strak. Design, Synthesis, and Biological Evaluation of Novel Oxadiazole- and Thiazole-Based Histamine H₃R Ligands. Bioorganic and Medicinal Chemistry. American Chemical Society (ACS) National Meeting, Orlando, Florida, March 30 – April 5, 2019.
- 2) Mohammad Khanfar, Design and Synthesis of Oxadiazole-Derived H₃ antagonist/Reversed Antagonist: Therapeutic Candidates for Neuronal Diseases, Network

Meeting of the Alexander von Humboldt Foundation Augsburg, Germany, 28 - 30 October 2015

- 3) Mohammad A. Khanfar, Mutasem Taha. Genetic Algorithm-Based K Nearest Neighbour and Multiple Linear Regression QSAR Modelling Coupled with Elaborate Pharmacophore Exploration followed by In Silico Screening Unveiled Low Nanomolar New mTOR Inhibitory Leads. American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, Nov 10-14, 2013, San Antonio, TX, USA.
- 4) Mohammad Khanfar, Mudit Mudit, Bhushan Awate, Girish Shah, Khalid El Sayed. Computer-Assisted Design of Novel Inhibitors for Metastatic Prostate Cancer. 6th Annual Louisiana Biomedical Research Network Meeting. January 25-27, 2008. New Orleans, LA.
- 5) Mohammad Khanfar, Mudit Mudit, Bhushan Awate, Girish Shah, Khalid El Sayed. Computer-Assisted Design of Novel Inhibitors for Metastatic Prostate Cancer. 8th Annual Student Research Symposium, ULM, Monroe, LA, April 30, 2008.
- 6) Dalia Abdelhalim, Hany Baraka, Mohammad Khanfar, Ahmed Orabi, Girish Shah, Khalid El Sayed. Rationale-design of anti-invasive 4-O-methyl-2, 7,11- cembratriene-4-6-diol. 8th Annual Student Research Symposium, ULM, Monroe, LA, April 30, 2008.
- 7) Mohammad Khanfar, Mudit Mudit, Bhushan Awate, Girish Shah, Khalid El Sayed. Computer-assisted design of novel latrunculin inhibitors for metastatic prostate cancer. Marine Natural Products Gordon Research Conference, February 2008, Ventura, CA.
- 8) El Sayed K, Khanfar M. Muralidharan A. Awate B. Youssef D. Girish S. Targeting cytoskeleton signaling in cancer: Rationale design of semisynthetic latrunculin analogs as inhibitors for metastatic prostate cancer. American Association for Cancer Research Annual Meeting, April 12-16, 2008, Los Angeles California.
- 9) Mudit M, Khanfar M, Muralidharan A, Thomas S, Shah GV, El Sayed KA. Discovery, design, and synthesis of anti-metastatic lead phenylmethylene hydantoins. American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, Nov 8-12, 2009, Los Angeles, CA.
- 10) Shah GV, Muralidharan A, Shibu T, Mudit M, Khanfar M, El Sayed KA. Identification of a small molecule(s) class to augment cell-cell adhesion and attenuate prostate tumor growth and metastasis. American Association for Cancer Research. 100th Annual Meeting, April 18-22, 2009, Denver, CO.
- 11) Mudit M, Khanfar M, Awate B, Shah GV, El Sayed KA. Optimization of novel marine-derived leads as potential treatment for metastatic prostate cancer. 6th Louisiana Biomedical Research Network Meeting, January 25-27, 2008, New Orleans, LA.
- 12) El Sayed KA, Khanfar M, Mudit M, Baraka H, Awate B, Shah GV. Discovery, design, synthesis, and development of new leads for treatment of metastatic prostate cancer inspired by marine natural products. 6th Louisiana Biomedical Research Network Meeting, January 25-27, 2008, New Orleans, LA.
- 13) Mohammad Khanfar, Ronald Hill, Amal Kaddoumi, Khanlid El Sayed. Computer-Assisted Discovery, Design, Synthesis, In Vitro, and In Vivo Evaluations of Highly Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 β . American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, Nov 13-18, 2010,

New Orleans, LA.

Teaching experience of the following courses:

- 1) Medicinal Chemistry I.
- 2) Medicinal Chemistry II
- 3) Medicinal Chemistry III
- 4) Pharmaceutical Analytical Chemistry.
- 5) Advanced Organic Chemistry.
- 6) Pharmaceutical Organic Chemistry.
- 7) Pharmaceutical Instrumental Analysis.

Advising Graduate Students Projects, Selected:

- 1) Co-advisor of the master student Safa'a Amaireh, thesis title: The use of ligand – based modeling followed by in vitro assay for the discovery of new Spleen Tyrosine Kinase inhibitors.
- 2) Major advisor of the master student Shada Alabed, thesis title: Computer aided drug design and discovery of new Fibroblast Growth Factor Receptor 1 inhibitors (FGFR1) followed by in vitro assay.
- 3) Co-advisor of the master student Layth Shdeifat, thesis title: The use of computer aided ligand-based modeling followed by in vitro assay for the discovery of new Epidermal Growth Factor Receptor (EGFR) inhibitors.
- 4) Major advisor of the master student Wafa'a Mera, thesis title: Discovery of new agents for B cell Malignancies and Inflammatory Diseases as Bruton's Tyrosin Kinase inhibitors via ligand-based pharmacophore modeling, structure-based modeling, QSAR analysis and in vitro validation.
- 5) Co-advisor of the master student Sara Maraba, thesis title: Prodrug approach to enhance percutaneous absorption of Azelaic acid.
- 6) Co-advisor of the master student Rasha Bashatwah, thesis title: Towards the discovery of new inhibitors against the highly conserved protein ppk1 followed by validation against relevant bacterial species.

Funded Research Projects

- 1) Project Title: "Design and discovery of new Mammalian Target of Rapamycin (mTOR) inhibitors". (JOD14,600, Deanship of Academic research, University of Jordan-2011).
- 2) Project Title: "Design and discovery of new SIRT2 inhibitors with significant therapeutic application in Alzheimer's, Parkinson's and Huntington Diseases." (JOD 5,000, Deanship of Academic research, University of Jordan-2013).
- 3) Project title:" Purification of Pathogenesis Determinant Proteins for the Identification of Novel Antimicrobial Targets: Polyphosphate Kinase 1 Active Site

Characterization". (JOD129000, Scientific Research Support Fund, The Ministry of Higher Education, Jordan-2014).

- 4) Project Title: "Reliance on Molecular Dynamics Simulation Implemented on a Single Ligand-Protein Complex for Development of Valid Pharmacophore Model(s): Protein Kinase C Theta as a case study". (JOD 25,000, Deanship of Academic research, University of Jordan-2015).
- 5) Project title: "Preparation of new thermo-responsive PLGA-polyether amine nanoparticles for drug delivery applications" (JOD 27,000, Deanship of Academic research, University of Jordan-2015).
- 6) Project title: "Design and Synthesis of Oxadiazole-Derived H3 antagonist/Reversed Antagonist: Therapeutic Candidates for Neuronal Diseases" (JOD 10,600, Deanship of Academic research, University of Jordan-2017).
- 7) Project title: "Design and Synthesis of Thiazol-Derived H3 antagonist/Reversed Antagonist: Therapeutic Candidates for Alzheimer's Disease" (SAR 100,000, Office of Research and Graduate Studies, Alfaisal University 2018).
- 8) Project title: "Discovery of Novel Mpro Inhibitors as Therapeutic Candidates of SARS-CoV-2 Infection" (SAR 50,000, Office of Research and Graduate Studies, Alfaisal University 2023).

Member in Professional Organizations

- American Chemical Society (ACS).
- American Association of Pharmaceutical Sciences (AAPS).
- Jordan Pharmaceutical Association.
- Bioequivalence committee in Jordanian Food and Drug Administration (JFDA).
- Quality Control committee in Jordanian Food and Drug Administration (JFDA).